Compare Bristol-Myers Squibb Co (BMY) vs iShares Silver Trust (SLV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs iShares Silver Trust — how do they compare? Bristol-Myers Squibb Co trades at $58.54 (market cap $116.30B), while iShares Silver Trust trades at $52.77. The key difference: Bristol-Myers Squibb Co pays a 4.42% dividend while iShares Silver Trust pays none, and Bristol-Myers Squibb Co is trading nearer its 52-week high, iShares Silver Trust nearer its low. Which is the better fit depends on your goals.
| BMY | SLV | |
|---|---|---|
Market Cap | $116.30B | — |
Sector | Health | — |
52-Week High | $62.37 | $105.57 |
52-Week Low | $42.60 | $33.32 |
Enterprise Value | $152.24B | — |
Dividend Yield | 4.42% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.
BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.
SLV (iShares Silver Trust) is trading at $52.16, down 3.32% amid broader precious metals weakness. The ETF shows bearish technical signals with moving averages and ADX indicators pointing lower, though RSI readings suggest potential oversold conditions. Recent news highlights silver's dual role as both industrial metal and store of value, with prices down 17.8% year-to-date according to Barron's (July 13, 2026).
Silver's outlook remains challenged by inflation fears and Fed policy uncertainty, though some analysts see potential for recovery to $55-60 range (StoneX Q3 Outlook, July 10, 2026). Key risks include dollar strength, industrial demand fluctuations, and ongoing geopolitical tensions affecting precious metals markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About iShares Silver Trust
The ETF seeks to reflect such performance before payment of the ETF's expenses and liabilities. It is not actively managed. The ETF does not engage in any activities designed to obtain a profit from, or to ameliorate losses caused by, changes in the price of silver.
Read more on SLV →
